Key result
Vitamin D3 supplementation improved arterial stiffness in a dose-response manner, with the 4,000 IU/day dose reducing carotid-femoral pulse wave velocity by a mean of 0.70 m/s compared to a 0.13 m/s increase with placebo.
Why the study?
Does vitamin D3 supplementation improve arterial stiffness in overweight African Americans with vitamin D deficiency?
RCT (n=70)
Double-blind
Randomized
No
Does vitamin D3 supplementation improve arterial stiffness in overweight African Americans with vitamin D deficiency?
Effect estimate: Mean change -0.70 m/s (for 4,000 IU/day group) (95% CI -1.07, -0.32)
Absolute Event Rate: -0.7% vs 0.13%
p-value: p=<0.01
Vitamin D3 supplementation improved arterial stiffness in a dose-dependent manner in overweight African Americans with vitamin D deficiency.
Supports vitamin D3 supplementation to reduce arterial stiffness in deficient overweight African Americans; extends evidence with RCT confirmation of dose-dependent effects.
BACKGROUND: Clinical trials are scant and equivocal on whether vitamin D can ameliorate arterial stiffness, particularly in populations at high risk for vitamin D deficiency and cardiovascular disease (CVD). This study determined the dose-response effects of vitamin D3 supplementation on arterial stiffness in overweight African Americans with vitamin D deficiency. METHODS: Seventy overweight African Americans (aged 13-45 years) with serum 25-hydroxyvitamin D [25(OH)D] levels ≤ 20 ng/mL were randomized to monthly oral supplementation of 18,000 IU (~600 IU/day, n = 17), 60,000 IU (~2000 IU/day, n = 18), or 120,000 IU (~4000 IU/day, n = 18) of vitamin D3 or placebo (n = 17) for 16-weeks. The arterial stiffness measurements, carotid-femoral pulse wave velocity (PWV) and carotid-radial PWV, were assessed by applanation tonometry at baseline and 16 weeks. RESULTS: Vitamin D3 supplementation demonstrated a dose-response increase in serum 25(OH)D concentrations between groups (P<0.01). A significant downward linear trend was observed for carotid-femoral PWV (P<0.01), as the mean changes in carotid-femoral PWV across the four treatment groups were 0.13 m/s (95% CI: -0.24, 0.51 m/s) for placebo, 0.02 m/s (95% CI: -0.34, 0.38 m/s) for 600 IU/day group, -0.11 m/s (95% CI: -0.50, 0.27 m/s) for the 2,000 IU/day group, and -0.70 m/s (95% CI: -1.07, -0.32 m/s) for the 4,000 IU/day group. Findings were similar for carotid-radial PWV (P = 0.03), as the mean changes in carotid-radial PWV across the four treatment groups were 0.24 m/s (95% CI: -0.45, 0.92 m/s) for placebo, 0.09 m/s (95% CI: -0.54, 0.73 m/s) for 600 IU/day group, -0.57 m/s (95% CI: -1.20, 0.07 m/s) for the 2,000 IU/day group, and -0.61 m/s (95% CI: -1.25, 0.02 m/s) for the 4,000 IU/day group. CONCLUSION: Arterial stiffness was improved by vitamin D3 supplementation in a dose-response manner in overweight African Americans with vitamin D deficiency.
No takes yet. Share an insight, caveat, or question.
Raed et al. (2017) conducted an RCT in Vitamin D deficiency and overweight/obesity (n=70). Vitamin D3 vs. Placebo was evaluated on Change in carotid-femoral pulse wave velocity (PWV) (Mean change -0.70 m/s (for 4,000 IU/day group), 95% CI -1.07, -0.32, p=<0.01). Vitamin D3 supplementation improved arterial stiffness in a dose-response manner, with the 4,000 IU/day dose reducing carotid-femoral pulse wave velocity by a mean of 0.70 m/s compared to a 0.13 m/s increase with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: